ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,767.50
0.10%
S&P ASX All Technology
3,137.90
0.55%
Brent Oil
84.85
0.00%
US Dollar vs AUD
1.49566
0.00%
Bitcoin
60,807.75
0.82%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuBase Therapeutics Inc (NBSE)

  7. NeuBase Therapeutics Inc (NBSE) News

NBSE

NeuBase Therapeutics (NBSE)

NeuBase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBSE
DateTimeSourceHeadlineSymbolCompany
28/06/202407:25Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBSENeuBase Therapeutics Inc
28/06/202407:20Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202407:18Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202407:16Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202407:15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202406:53Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202406:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202406:47Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBSENeuBase Therapeutics Inc
28/06/202406:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
04/06/202406:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
01/06/202406:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
23/05/202406:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
17/05/202400:07Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NBSENeuBase Therapeutics Inc
14/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
06/05/202421:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NBSENeuBase Therapeutics Inc
06/04/202407:05GlobeNewswire Inc.NeuBase Therapeutics Announces Receipt of Notice from NasdaqNASDAQ:NBSENeuBase Therapeutics Inc
08/03/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
24/02/202408:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
27/01/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
17/01/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/12/202322:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NBSENeuBase Therapeutics Inc
22/12/202322:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
28/11/202301:00GlobeNewswire Inc.Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNASDAQ:NBSENeuBase Therapeutics Inc
10/11/202308:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBSENeuBase Therapeutics Inc
07/11/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
07/11/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
20/10/202322:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
18/10/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
30/09/202306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBSENeuBase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NBSE

Your Recent History

NASDAQ
AAWSHXX
Jpmorgan Chase Financial...
TSX
AIF
Altus
EU
FR001400PFC2
SG Issuer Sg Issuer Mc M...
BIT
F39562
Vontobel Financial Produ...
DBI
DE3A
Frankfurt DAX Indication...
TG
NMR
Nova
POLO
SNXBTC
Synthetix Network Token
BIT
FC735L
Vontobel
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved